Meet the team
Dr David Almeida, MD, MBA, PhD, Executive Chairman
Dr David Almeida, MD, MBA, PhD, Executive Chairman
Dr David Almeida, MD, MBA, PhD, Executive Chairman
Dr. David Almeida is a renowned retina surgeon with an impressive combination of MD, MBA, and PhD qualifications, specializing in pioneering clinical trials and innovative treatments in ophthalmology. His commitment to advancing medical science is evidenced by his leadership in developing groundbreaking therapies and his active role in the ophthalmic community.
Greg Vico, CEO
Dr David Almeida, MD, MBA, PhD, Executive Chairman
Dr David Almeida, MD, MBA, PhD, Executive Chairman
Greg Vico is a dynamic clinical trial strategist who has spent the last decade enhancing the efficiency and effectiveness of phase III trials in oncology. His expertise in regulatory compliance and patient recruitment strategies has helped to streamline processes and accelerate drug approval timelines.
Bruno Gagnon, COO
Dr David Almeida, MD, MBA, PhD, Executive Chairman
Bruno Gagnon, COO
Bruno Gagnon is a 30-year biopharma veteran. He is an opinion leader and influencer in the field of Clinical Trial Execution with expertise in ophthalmology and rare disease. He is former Senior Vice President of Clinical Operations at Opthea (2022-2024) and BridgeBio (2017-2022). He also led Clinical Operations at BioMarin Pharmaceuti
Bruno Gagnon is a 30-year biopharma veteran. He is an opinion leader and influencer in the field of Clinical Trial Execution with expertise in ophthalmology and rare disease. He is former Senior Vice President of Clinical Operations at Opthea (2022-2024) and BridgeBio (2017-2022). He also led Clinical Operations at BioMarin Pharmaceutical (2011-2015) biotech company focusing on rare and ultra-rare diseases.
Bruno’s expertise focuses on planning and execution of clinical trials with a special focus on quality, regulatory inspections, site engagement and optimization of patient recruitment.
Bruno holds a bachelor's degree from the School of Pharmacy, Laval University and a Master's in Pharmaceutical Sciences from University of Montreal.